RE:RE:Merck USA (MSD) acquires Phase 2 blood cancer co - US$1.35BWith Merck USA paying up big for Phase 2 single indication blood cancer - this confirms that Big Pharma is in significant need of innovative cancer drugs to face off the challenge of a looming patent cliff by 2025 and every new cancer drug in development is on the table for their immediate acquisition, more particularly immuno-oncology platform therapy drugs like ONCY'S pelareorep which can be used in multiple cancers with multiple existing I/O agents like immune checkpoint inhibitors for example.